ClinicalTrials.gg
CompletedNCT07554781Updated Nov 20, 2026

A Single-Center, Retrospective Study to Improve the Visibility of Breast Tissue Marker Clips in Breast Tissue and Axillary Lymph Nodes Using the Color Doppler Twinkling Artifact

An observational study in Breast Cancer, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Completed at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

How we know

Updated Nov 20, 2026Now CompletedFirst site in China+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
73
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — 59 open to participants now, 67 under way, 18 of them phase 3. Breast Neoplasms · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Enrollment
25th of 29
73 · median 220
Started
2026
with 14 others
Observational
29 of 101
11 open now
Registered
81st of 101
by date

Among the 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, this one is the 25th largest by enrollment of the 29 observational ones that give a count, is one of 15 that started in 2026, is one of 29 observational ones, and was the 81st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

59 of the 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University are open now, in 1 country. Recruiting first, the newest first:

54 more — sign in →

By country, each count listing its studies:

All 59 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, or all of them as a file.
02

Study summary

This single-center, retrospective study aims to evaluate the utility of the color Doppler twinkling artifact feature in improving the visibility of breast tissue marker clips within breast tissue and axillary lymph nodes. The study population will consist of approximately 86 female patients (with 110 clips) who have undergone placement of breast tissue marker clips and have corresponding preoperative imaging data from GE-10 or Siemens ultrasound systems between October 2024 and October 2025. The primary endpoint is the proportion of subjects whose implanted clips exhibit the characteristic "twinkling artifact" on color Doppler ultrasound imaging, reported with a 95% confidence interval.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People who have had a breast tissue marker clip placed in their breast or underarm area.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged ≥18 years.
  • Presence of suspicious breast lesions confirmed by ultrasound.
  • Successful implantation of a breast tissue marker clip with accurate radiological documentation.
  • Availability of preoperative breast ultrasound examinations (including B-mode and Color Doppler) performed using either a GE-10 or Siemens ultrasound system.
  • Confirmation of clip placement via mammography, surgical specimen morphology, or same-day post-implantation ultrasound.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation.
  • History of ipsilateral breast or surgery.
  • Presence of other metal implants potentially interfering with imaging.
  • Suspicious mammographic microcalcifications in the target lesion.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
73 participants (actual)
Patient registry
No

Groups and cohorts

  • Conventional Ultrasound and Twinkling Artifact Group

    Patients examined using both B-mode ultrasound and color Doppler ultrasound (with twinkling artifact assessment).

06

What researchers measure

Primary outcomes

  1. Proportion of subjects exhibiting the "Twinkling Artifact" posterior to the marker clip on Color Doppler Ultrasound.

    Time frame: From May 2026 to May2027

Secondary outcomes

  1. Rate of successful breast-conserving surgery.

    Time frame: From January 2026 to January 2027

  2. Re-operation rate, defined as cases with negative intraoperative margins but positive cancerous margins on final postoperative pathology.

    Time frame: From January 2026 to January 2027

  3. Inter-observer agreement rate in interpreting B-mode ultrasound visibility and Twinkling Artifact results among different radiologists.

    Time frame: From January 2026 to January 2027

  4. Proportion of subjects in whom the marker clip appears as a "hyperechoic structure" on conventional B-mode ultrasound.

    Time frame: From January 2026 to January 2027

  5. Positive margin rate.

    Time frame: From January 2026 to January 2027

07

Study locations

1 site
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Guangzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2026 to primary completion in Jul 2026, 2 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion May 2027 → Jul 2026 and completion May 2027 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Apr 28, 2026
StartActual
May 1, 2026
Primary completionActual
Jul 1, 2026was May 2027
CompletionActual
Jul 1, 2026was May 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 20, 2026
Sites
1 site added — first site in China
Show site
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, China
Nov 20, 2026
Primary completion
May 2027→Jul 1, 2026 (actual)
Nov 20, 2026
Study completion
May 2027→Jul 1, 2026 (actual)
Nov 20, 2026
Enrollment
86 (estimated)→73 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Completed
    1 site added — first site in China
    Show site
    • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, China
    Primary completion May 2027→Jul 1, 2026 (now actual)
    Study completion May 2027→Jul 1, 2026 (now actual)
    Enrollment 86 (estimated)→73 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07554781
Responsible party
Chang Gong (Professor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Apr 28, 2026
Start date
May 1, 2026
Primary completion
Jul 1, 2026
Completion
Jul 1, 2026
Last update
Nov 20, 2026

Study contacts

Chang Gong
study director · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion